A publication referencing ipamorelin appeared on April 27, 2026, in the International Journal of Molecular Sciences. The article is titled "Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives."
The publication is listed under PubMed ID 42123471. It addresses therapeutic peptides broadly, including their effects, safety, and clinical applications across aesthetic, metabolic, and endocrine conditions.
Ipamorelin remains classified as an unapproved compound intended for research use only. This publication is noted as a new addition to the scientific literature discussing therapeutic peptides.
No specific findings, results, or conclusions from the publication are detailed here. Readers interested in the full content of the review should consult the original source directly.
For further background on ipamorelin, readers can refer to the compound overview.